GenMark Diagnostics, Inc (GNMK) SVP Michael Gleeson Sells 10,000 Shares of Stock

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Michael Gleeson sold 10,000 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $7.51, for a total value of $75,100.00. Following the sale, the senior vice president now directly owns 373,101 shares in the company, valued at $2,801,988.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Gleeson also recently made the following trade(s):

  • On Wednesday, February 27th, Michael Gleeson sold 26,704 shares of GenMark Diagnostics stock. The shares were sold at an average price of $7.96, for a total value of $212,563.84.
  • On Wednesday, February 20th, Michael Gleeson sold 2,121 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.16, for a total value of $13,065.36.

Shares of GNMK opened at $7.32 on Wednesday. The company has a market capitalization of $420.15 million, a PE ratio of -8.04 and a beta of 1.57. The company has a debt-to-equity ratio of 1.07, a quick ratio of 2.87 and a current ratio of 3.37. GenMark Diagnostics, Inc has a one year low of $3.58 and a one year high of $8.81.

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Thursday, February 21st. The medical equipment provider reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05). The business had revenue of $19.38 million during the quarter, compared to analyst estimates of $19.22 million. GenMark Diagnostics had a negative return on equity of 107.77% and a negative net margin of 71.37%. On average, sell-side analysts expect that GenMark Diagnostics, Inc will post -0.74 EPS for the current fiscal year.

A number of research firms have weighed in on GNMK. BidaskClub raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, January 7th. Zacks Investment Research downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, February 12th. William Blair reaffirmed an “outperform” rating on shares of GenMark Diagnostics in a report on Friday, December 21st. Finally, Raymond James set a $7.00 price objective on GenMark Diagnostics and gave the company a “buy” rating in a report on Thursday, December 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $9.75.

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of GenMark Diagnostics by 0.4% in the 4th quarter. FMR LLC now owns 8,393,292 shares of the medical equipment provider’s stock worth $40,791,000 after acquiring an additional 30,334 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of GenMark Diagnostics by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,414,814 shares of the medical equipment provider’s stock worth $32,448,000 after acquiring an additional 36,100 shares in the last quarter. Casdin Capital LLC boosted its holdings in shares of GenMark Diagnostics by 9.0% in the 4th quarter. Casdin Capital LLC now owns 3,815,000 shares of the medical equipment provider’s stock worth $18,541,000 after acquiring an additional 315,000 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of GenMark Diagnostics by 0.8% in the 4th quarter. BlackRock Inc. now owns 3,638,332 shares of the medical equipment provider’s stock worth $17,683,000 after acquiring an additional 28,537 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of GenMark Diagnostics by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,613,213 shares of the medical equipment provider’s stock worth $19,207,000 after acquiring an additional 34,940 shares in the last quarter. 94.21% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “GenMark Diagnostics, Inc (GNMK) SVP Michael Gleeson Sells 10,000 Shares of Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2019/04/17/genmark-diagnostics-inc-gnmk-svp-michael-gleeson-sells-10000-shares-of-stock.html.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Featured Article: What is a Call Option?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.